Related Experiment Video
Updated: Mar 8, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.7K
Low Dose Cyclophosphamide Therapy in Lichen Amyloidosis
Indian Journal of Dermatology, Venereology and Leprology
|February 2, 2017
Summary
Cyclophosphamide treatment significantly reduced itching in lichen amyloidosis patients. While some saw papule improvement, others experienced no change, and side effects like leucopenia and alopecia were noted.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Lichen amyloidosis is a chronic pruritic skin condition.
- Limited effective treatments exist for lichen amyloidosis.
Purpose of the Study:
- To evaluate the efficacy and safety of oral cyclophosphamide in treating lichen amyloidosis.
Main Methods:
- Nine patients with lichen amyloidosis received 50 mg of oral cyclophosphamide daily.
- Treatment duration ranged from 6 months to 1 year.
- Patients were monitored for symptom improvement and side effects.
Main Results:
- All 9 patients experienced an 80-90% reduction in itching within 4 months.
- Four patients showed 50-75% papule improvement after 6 months, with no further change.
- Three patients had no change in papules; one developed reversible leucopenia, and three had transient alopecia.
Conclusions:
- Oral cyclophosphamide effectively alleviates itching in lichen amyloidosis.
- Papule improvement is variable and may not be sustained.
- Potential side effects include leucopenia and alopecia, requiring monitoring.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
588
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
588
01:21Drugs for Treatment of Constipation-Predominant IBS
1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
579
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
579